Scott Burwell is an experienced intellectual property litigator. He focuses his practice primarily on Hatch-Waxman (ANDA) litigations, as well as other pharmaceutical and biotechnology-related disputes. He has broad experience in all facets of litigation, including bench and jury trials in federal district courts and appellate practice before the U.S. Court of Appeals for the Federal Circuit. For more than 20 years, Scott has represented pharmaceutical companies on matters involving blockbuster drugs such as Zyprexa®, Evista®, Strattera®, and Enbrel®. He was recognized in Managing IP Handbook as "a fantastic writer, someone who can take sometimes very abstract scientific principles and truly abstract intellectual property principles, and reduce that to a written document that is clear, concise and understandable." Scott regularly publishes and lectures on various issues of patent law. He has been an adjunct professor at Howard University School of Law since 2007, teaching patent law and public policy courses. Scott serves on the firm's management committee, and previously served as the hiring partner for Finnegan's Washington, D.C., and Reston offices. He is heavily involved in diversity and retention initiatives. Scott is a faculty member of the National Institute of Trial Advocacy's Building Trial Skills and Deposition Skills programs. He is an advisory board member of Bloomberg BNA's Pharmaceutical Law and Industry Report, and on the board of directors for the Washington Lawyers' Committee for Civil Rights and Urban Affairs.